The Blind Start is a novel design whereby subjects will be randomized to one of 4 groups, each representing a different treatment sequence, and cross over to UX003 at different pre-defined time points in a blinded manner. All groups will receive a minimum of 24 weeks treatment with 4 mg/kg UX003 every other week.